Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
Yecuris adds value to pre-clinical drug development programs with our proprietary liver-humanized FRG® KO mouse technologies and related contract services. From tissue targeting to identifying off-target effects or modeling for multi-species preclinical development pathways, FRG provides utility for many gene editing and gene therapy programs. Whether you want mice with human hepatocytes harboring genetic and metabolic disorders or want in vivo cross-species comparisons with our new HepaSpecies™ xenograft service, Yecuris can help de-risk and advance your program.
Contact us today!
Language:
English
Who can attend? Everyone
Featured Presenters
CEO
As CEO of Yecuris Corporation, Rob leads the organization in its mission to deliver scientific discovery and project success to all customers
Staff Scientist & Study Director
Lander completed his PhD and post-doctoral research on the application of humanized mice for infectious diseases. Now, as Yecuris’ Study Director, he designs studies for gene therapy clients across the globe.
Operations Manager
Sean brings over 20 years of experience in biomedical research to Yecuris. He directed a project that pioneered the first universal selection system for lentiviral and AAV gene therapies.
Client Services Group Manager
Greg started at Yecuris 10 years ago as an Associate Scientist developing liver-humanized FRG mice. He now serves as the CSG Manager overseeing tech support, sales and marketing activities.
Technical Specialist
Mimi specializes in FRG colony management and technical procedures while serving on both the manufacturing and CSG teams.
Technical Specialist
Franchesca oversees both in vivo and reagent orders as well as the customer service aspect of the CSG team at Yecuris.
Hosted By
The full session archive, available exclusively for attendees of the American Society of Gene & Cell Therapy's 23rd Annual Meeting, May 12-15, 2020.
Documents